PURPOSE: To analyze the role of lymph node dissection (LND) in patients with large renal tumors. METHODS: We performed a retrospective study of patients with renal cell carcinoma ≥7 cm in size undergoing surgery between 1990 and 2012. Primary outcome measures were recurrence-free and overall survival of patients who did and did not undergo LND. Cox proportional hazards regression models were created to account for known risk factors for recurrence and survival. Secondary outcomes were recurrence-free and overall survival by lymph node status, lymph node template and number of lymph nodes removed. RESULTS: Of 524 patients, 164 had disease recurrence and 197 died. Median follow-up was 5 and 5.5 years for patients who did not die or have a recurrence, respectively. A total of 334 (64 %) patients underwent LND, and node-positive disease was identified in 26 (8 %). For patients who did and did not undergo LND, 5-year recurrence-free survival was 64 and 77 %, respectively. Five-year overall survival was 75 and 78 %, respectively. LND was not a predictor of recurrence or survival in multivariate analysis. Node-positive disease was associated with recurrence (p < 0.0005) and mortality (p = 0.032), although node-positive patients had a 5-year overall survival of 65 %. CONCLUSIONS: We did not find a difference in recurrence-free or overall survival in patients with ≥7-cm tumors whether or not they underwent LND. Node-positive disease was associated with worse outcomes, suggesting that LND provides important staging information that can be important in the design of adjuvant clinical trials.
PURPOSE: To analyze the role of lymph node dissection (LND) in patients with large renal tumors. METHODS: We performed a retrospective study of patients with renal cell carcinoma ≥7 cm in size undergoing surgery between 1990 and 2012. Primary outcome measures were recurrence-free and overall survival of patients who did and did not undergo LND. Cox proportional hazards regression models were created to account for known risk factors for recurrence and survival. Secondary outcomes were recurrence-free and overall survival by lymph node status, lymph node template and number of lymph nodes removed. RESULTS: Of 524 patients, 164 had disease recurrence and 197 died. Median follow-up was 5 and 5.5 years for patients who did not die or have a recurrence, respectively. A total of 334 (64 %) patients underwent LND, and node-positive disease was identified in 26 (8 %). For patients who did and did not undergo LND, 5-year recurrence-free survival was 64 and 77 %, respectively. Five-year overall survival was 75 and 78 %, respectively. LND was not a predictor of recurrence or survival in multivariate analysis. Node-positive disease was associated with recurrence (p < 0.0005) and mortality (p = 0.032), although node-positive patients had a 5-year overall survival of 65 %. CONCLUSIONS: We did not find a difference in recurrence-free or overall survival in patients with ≥7-cm tumors whether or not they underwent LND. Node-positive disease was associated with worse outcomes, suggesting that LND provides important staging information that can be important in the design of adjuvant clinical trials.
Authors: Amnon Zisman; Allan J Pantuck; Jeffery Wieder; Debby H Chao; Fredrick Dorey; Jonathan W Said; Jean B deKernion; Robert A Figlin; Arie S Belldegrun Journal: J Clin Oncol Date: 2002-12-01 Impact factor: 44.544
Authors: C Terrone; S Guercio; S De Luca; M Poggio; E Castelli; C Scoffone; R Tarabuzzi; R M Scarpa; D Fontana; S Rocca Rossetti Journal: BJU Int Date: 2003-01 Impact factor: 5.588
Authors: Allan J Pantuck; Amnon Zisman; Fredrick Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun Journal: J Urol Date: 2003-06 Impact factor: 7.450
Authors: Andrew J Stephenson; Michael P Chetner; Keith Rourke; Martin E Gleave; M Signaevsky; Bruce Palmer; James Kuan; Gerald B Brock; Simon Tanguay Journal: J Urol Date: 2004-07 Impact factor: 7.450
Authors: Alain Kaldany; Zev R Leopold; Juliana E Kim; Hiren V Patel; Arnav Srivastava; Alexandra L Tabakin; Eric A Singer Journal: Kidney Cancer J Date: 2020-12
Authors: Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer Journal: Front Oncol Date: 2017-05-31 Impact factor: 6.244
Authors: Janine Bacic; Tao Liu; R Houston Thompson; Stephen A Boorjian; Bradley C Leibovich; Dragan Golijanin; Boris Gershman Journal: Urology Date: 2020-03-04 Impact factor: 2.649